Status:
NOT_YET_RECRUITING
Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Parkinson's Disease
Lead Sponsor:
Istituto Nazionale di Ricovero e Cura per Anziani
Conditions:
Parkinson Disease
Eligibility:
All Genders
65+ years
Brief Summary
BioGenParkinson is an observational, prospective cohort study evaluating biomarkers of Parkinson's Disease (PD) progression in community-dwelling subjects aged 65 years or more, consecutively referrin...
Detailed Description
The objective of the BioGenParkinson study is the evaluation of the prognostic accuracy of epigenetic, genetic and protein biomarkers in relation to Parkinson's Disease (PD) motor symptoms progression...
Eligibility Criteria
Inclusion
- PD at Hoehn and Yahr stage ≤3
- MMSE test ≥24 score
Exclusion
- MMSE score \< 24
- Severe cardiovascular diseases (including congestive heart failure NYHA=4, acute coronary syndrome, stroke)
- History of traumatic brain injury, previous deep brain surgery
- Current substance or alcohol abuse
- Reduced life expectancy less than six months
Key Trial Info
Start Date :
May 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 30 2026
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT05384522
Start Date
May 30 2024
End Date
January 30 2026
Last Update
March 5 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.